25,729 articles
Fatty liver disease
Fatty liver disease, now called MASLD (formerly NAFLD), is excess liver fat not caused by alcohol, ranging from simple steatosis to MASH with fibrosis; treated with weight loss, resmetirom, and semaglutide.
Favezelimab
Favezelimab (MK-4280), Merck's humanized anti-LAG-3 IgG4 antibody, was tested with pembrolizumab (MK-4280A) in colorectal cancer and Hodgkin lymphoma; development was discontinued in December 2024 after phase 3 KEYFORM-007 missed overall survival.
Favipiravir
Favipiravir (Avigan, T-705, Favilavir) is a broad-spectrum antiviral from Toyama Chemical/Fujifilm that inhibits viral RNA polymerase by lethal mutagenesis; approved in Japan in 2014 for pandemic influenza, trialed widely for COVID-19 and Ebola with limited evidence of benefit.
FAVOR trial
FAVOR trial (Fimasartan, Atenolol, and Valsartan On haemodynamic paRameters in ischaemic stroke), NCT02403349: 12-week Korean double-blind randomized trial, 105 patients, showing ARBs lowered central BP and cerebral pulsatility more than atenolol.
FAWD study
The FAWD study (Factors Associated With Dermatoporosis) was a Mexican cross-sectional study that found dermatoporosis in 29% of 315 patients over 60, linked to age, sun exposure, and anticoagulants.
Fazamorexant
Fazamorexant (YZJ-1139, brand Mengping) is a dual orexin receptor antagonist for insomnia developed by Yangtze River Pharmaceutical, approved in China on 21 May 2026 as the first domestically developed DORA, with IC50 32/41 nM and half-life about 2–4 hours.
Fazirsiran
Fazirsiran (TAK-999, ARO-AAT) is an investigational siRNA therapy by Arrowhead and Takeda that degrades Z-AAT mRNA to treat alpha-1 antitrypsin deficiency liver disease; phase 2 trials showed ~94% liver Z-AAT reduction and fibrosis regression.
FB825
FB825 is a humanized monoclonal antibody developed by Oneness Biotech to treat IgE-related allergic diseases such as atopic dermatitis and allergic asthma, out-licensed to LEO Pharma in 2020.
FCLADHAAASDFSQ trial
FCLADHAAASDFSQ (NCT07376148) is a phase 4, single-group, open-label trial at Instituto de Oftalmología Fundación Conde de Valenciana, Mexico City, testing topical hyaluronic acid, ascorbic acid, and sodium DNA after fractional CO2 laser for photoaged facial skin in 30 participants, with SASSQ as the primary outcome.
FCN-338 (LOXO-338)
FCN-338 (LOXO-338, LY3847429) is an oral selective BCL-2 inhibitor developed by Fochon Pharmaceuticals (Fosun Pharma), licensed to Eli Lilly in 2020, discontinued by Lilly in 2022, and still in Phase I/II trials in China.
FD-SAC BAS study
FD-SAC BAS (NCT07754188) is a prospective real-world cohort study at three Chinese centers comparing 30-day stroke or death after flow diverter versus stent-assisted coiling in 274 patients with unruptured wide-neck bifurcation aneurysms.
Fe del Mundo
Fe del Mundo (1911-2011), Filipina pediatrician and first woman National Scientist of the Philippines; founded the country's first pediatric hospital (1957), researched dengue and childhood vaccines, invented a bamboo incubator.
Fear of cancer
Fear of cancer (carcinophobia, ICD-11 MG24.0) ranges from common population cancer worry to clinical nosophobia, illness anxiety disorder, and fear of cancer recurrence in survivors; treated with CBT.
Fear of cardiovascular disease
Fear of cardiovascular disease, known as cardiophobia or heart-focused anxiety, is a specific phobia involving repeated chest pain and palpitations with fear of heart attack, classified as ICD-11 code MG24.7.
Fear of death or dying
Fear of death or dying (death anxiety), ICD-11 code MG23, is fear of one's own and others' mortality; a transdiagnostic construct linked to anxiety, depression, and hypochondriasis, measured mainly by the Templer Death Anxiety Scale.
Fear of disease
Fear of disease is excessive anxiety about having or acquiring illness. It includes nosophobia, fear of one specific disease, and illness anxiety disorder, the DSM-5 name for hypochondria.
Fear of flying
Fear of flying (aerophobia, aviophobia) is a situational specific phobia affecting an estimated 10–40% of people, about 25 million U.S. adults. Treated mainly with exposure-based CBT and virtual reality exposure therapy.
Fear of human immunodeficiency virus
Fear of human immunodeficiency virus (ICD-11 MG24.1), also called HIV phobia, serophobia, or AIDS phobia, is a classified disease-fear condition: persistent, irrational fear of contracting HIV despite negative tests, first described 1983, closely tied to HIV stigma and testing anxiety.
Fear of mental disorder
Fear of mental disorder (ICD-11 MG24.J) is a chapter 24 category classifying fear of developing a mental disorder as a health-status factor, distinct from hypochondriasis (6B23) and bodily distress disorder, alongside sibling disease-fear codes.
Fear of the dark
Fear of the dark, clinically nyctophobia (also scotophobia, lygophobia), is a specific phobia of darkness causing panic, insomnia, and avoidance; common in children, treated with CBT and exposure therapy.
Febrile infection-related epilepsy syndrome
Febrile infection-related epilepsy syndrome (FIRES), also called AERRPS or DESC, is a rare NORSE-subtype epileptic encephalopathy: super-refractory status epilepticus begins 24 hours to 2 weeks after a febrile illness in previously healthy, mostly school-aged children, leaving drug-resistant epilepsy; incidence about 1 in 1,000,000.
Febrile seizure
Febrile seizure (febrile convulsion): a seizure triggered by fever (≥38°C) in children 6–60 months without CNS infection; affects 2–5% of children, recurs in 30–50%, benign prognosis, antipyretics do not prevent it.
Febuxostat
Febuxostat (Adenuric, Uloric) is a nonpurine xanthine oxidase inhibitor for hyperuricemia in gout, FDA-approved 2009; CARES showed higher cardiovascular death versus allopurinol, FAST did not, prompting a US boxed warning.
Fecal immunochemical test
A fecal immunochemical test (FIT) is a stool-based test using antibodies against human hemoglobin to detect hidden blood for colorectal cancer screening, done at home with no preparation.
Fecal impaction
Fecal impaction (fecaloma): a compacted fecal mass at any intestinal level that cannot be evacuated spontaneously, usually from chronic constipation in elderly or neuropsychiatric patients; treated with enemas, manual disimpaction, or polyethylene glycol lavage, and complicated by perforation, obstruction, stercoral ulcer, and urinary retention.
Fecal incontinence
Fecal incontinence, or accidental bowel leakage, is uncontrolled passage of stool, affecting about 7.7 percent of adults. Causes include sphincter damage, childbirth, and neurological disease; treatment is stepwise from diet and pelvic floor training to nerve stimulation and surgery.
Fecal microbiota transplant
Fecal microbiota transplant (FMT), also called fecal bacteriotherapy or intestinal microbiota transfer, transfers screened donor stool to a recipient, mainly to prevent recurrent C. difficile infection; delivered by colonoscopy, enema, tube, or capsules, with FDA-approved products Rebyota and Vowst.
Fecal microbiota transplantation
Fecal microbiota transplantation (FMT) is the transfer of processed stool from a screened healthy donor into a patient's gut, curing 80–90% of recurrent C. difficile infections.
Fecal occult blood test
A fecal occult blood test (FOBT) detects hidden blood in stool, screening for colorectal cancer; the guaiac-based form has largely been replaced by the more sensitive fecal immunochemical test.
Fecal–oral route
Fecal–oral route: indirect disease transmission in which pathogens exit in feces and enter a new host by mouth via food, water, fingers, flies, fields, or fomites; drives cholera, hepatitis A, norovirus.